Cancer investigation
-
Cancer investigation · May 2014
Multicenter StudySequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.
Of 93 patients with pretreated, BRAF(V600) mutation-positive advanced melanoma who received vemurafenib or dabrafenib before (n = 45) or after (n = 48) treatment with ipilimumab 3 mg/kg, median overall survival (mOS) from first treatment was 9.9 and 14.5 months, respectively. Among patients treated with a BRAF inhibitor first, mOS from the end of BRAF inhibition was 1.2 months for those who did not complete ipilimumab treatment as per protocol, compared with 12.7 months for those who did (p < .001). Prospective, randomized studies are required to determine the optimal sequencing of ipilimumab and BRAF inhibitors in patients with BRAF-mutated metastatic melanoma.
-
Cancer investigation · Mar 2014
Clinically relevant quality assurance for intensity modulated radiotherapy plans: gamma maps and DVH-based evaluation.
To explore a novel patient-dose DVH-based method for pretreatment dose quality assurance tests. ⋯ Our results underline the importance of QA-methods based on DVH-metrics to predict the impact of delivered dose.
-
Sirtuins are involved in the control of the cell cycle and regulation of gene transcription. While some sirtuins have tumor suppressor effects, others regulate tumors metabolism. ⋯ Sirtuins show strong potential to become a valuable predictive and prognostic marker for cancer and are eligible as therapeutic targets for a variety of tumors. Investigation of new molecules able to modulate sirtuins activity must be encouraged.
-
Cancer investigation · Jul 2013
The use of transdermal buprenorphine to relieve radiotherapy-related pain in head and neck cancer patients.
Many head and neck cancer (HNC) patients experience painful therapy-related mucositis and dermatitis. This prospective observational study evaluated transdermal buprenorphine use in HNC patients to relieve treatment-related pain. ⋯ These patients subsequently received transdermal buprenorphine. Pain therapy should be more accurately up-titrated to the maximum recommended dose (140 μg/hr) where necessary to maintain pain scores ≤30/100 and, for some patients, should be continued for 6 weeks after the last cancer treatment day.
-
Cancer investigation · Jun 2013
Multicenter StudySorafenib and everolimus in advanced clear cell renal carcinoma: a phase I/II trial of the SCRI Oncology Research Consortium.
To evaluate the feasibility and efficacy of sorafenib and everolimus in renal cell carcinoma (RCC). ⋯ Fifty percent doses of sorafenib and everolimus were required when these drugs were combined. No increase in efficacy was suggested; toxicity was modestly increased.